Prescient takes its PTX-100 trial to next level after Phase 1b success
In an update that endorses the potential benefits of Prescient Therapeutic’s (ASX:PTX) anti-cancer drug PTX-100,...
In an update that endorses the potential benefits of Prescient Therapeutic’s (ASX:PTX) anti-cancer drug PTX-100,...
Prescient Therapeutics (ASX:PTX) says its cancer-fighting drug candidate has exhibited an excellent safety in an...
Australian biotech company Prescient Therapeutics has successfully finished a round of safety testing on its...
Prescient Therapeutics (PTX) is progressing the trial of its cancer-blocking drug PTX100 following successful results...
The US Food and Drug Administration has assigned a fast track designation to a new...
Shares in biotech company, Prescient Therapeutics, have proved buoyant this week after initial immunogenicity testing...
In an upbeat development, Prescient Therapeutics Limited (ASX:PTX) has announced outstanding findings from in silico...
Shares in Prescient Therapeutics Ltd (ASX: PTX) have surged to fresh heights today on the back of news...
Prescient Therapeutics (PTX) says recent results from testing show its entire platform has been substantially...
The results significantly de-risk the project as PTX continues development of its OmniCAR platform. As...

This investor centre was built by Reach Markets
©2026 Reach Markets
To stay up to date with Prescient Therapeutics news and events, please register your details.